Multi-marker Approach for Risk Assessment in PAH

Multi-marker Approach for Risk Assessment in Pulmonary Arterial Hypertension (PAH)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03954405

Acronym

MARS

Enrollment

500

Registered

2019-05-17

Start date

2017-11-01

Completion date

2025-12-30

Last updated

2021-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Brief summary

Prospective registry including incident patients and prevalent patients which pretends to identify clinical characteristics, treatment trends in-hospital and ten years follow-up outcome through major adverse cardiovascular events (MACE) in a China population with well characterized PAH.

Detailed description

baseline include: An echocardiogram to assess the size, shape, pumping action and the extent of any damage to the heart. Lung function tests which include blowing measurements to assess gas volumes within the lungs as well as assessment of how the lungs exchange gases. Right heart catheterisation (RHC) to diagnose PAH Optional Cardiac Magnetic Resonance tests. 6 minute walk distance (6MWD). To measure exercise capacity Electrocardiogram (ECG), a test that measures the electrical activity of the heart Blood tests MACE include: death heart/lung transplantation atrial septostomy hospitalization due to worsening of PAH start of new specific PAH treatment persistent decrease of \>15% from baseline in 6MWD (or \>30% compared with last study-related measurement) persistent worsening of World Health Organization (WHO) Functional Class (FC）

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

1 Years to 85 Years

Healthy volunteers

Inclusion criteria

diagnosis of PAH (by RHC)

Exclusion criteria

Refusal to participate.

Design outcomes

Primary

Measure	Time frame	Description
survival	5 years	To recruit a cohort of group 1 PAH cases. define the death as the primary outcome

Secondary

Measure	Time frame	Description
clinical worsening	5 years	one of the following: death, heart/lung transplantation, atrial septostomy, hospitalization due to worsening of PAH, start of new specific PAH treatment, persistent decrease of \>15% from baseline in 6MWD (or \>30% compared with last study-related measurement), persistent worsening of WHO FC

Countries

China

Contacts

Primary ContactZheng Xusn

soniazheng@outlook.com+8618627885144

Outcome results